ATE279947T1 - Immunglobulinähnliche domäne mit erhöhten halbwertszeiten - Google Patents

Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Info

Publication number
ATE279947T1
ATE279947T1 AT97907993T AT97907993T ATE279947T1 AT E279947 T1 ATE279947 T1 AT E279947T1 AT 97907993 T AT97907993 T AT 97907993T AT 97907993 T AT97907993 T AT 97907993T AT E279947 T1 ATE279947 T1 AT E279947T1
Authority
AT
Austria
Prior art keywords
domains
antibody
increased
half lives
immunoglobulin
Prior art date
Application number
AT97907993T
Other languages
English (en)
Inventor
Elizabeth Sally Ward
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE279947T1 publication Critical patent/ATE279947T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT97907993T 1996-03-18 1997-03-03 Immunglobulinähnliche domäne mit erhöhten halbwertszeiten ATE279947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1356396P 1996-03-18 1996-03-18
PCT/US1997/003321 WO1997034631A1 (en) 1996-03-18 1997-03-03 Immunoglobin-like domains with increased half lives

Publications (1)

Publication Number Publication Date
ATE279947T1 true ATE279947T1 (de) 2004-11-15

Family

ID=21760590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907993T ATE279947T1 (de) 1996-03-18 1997-03-03 Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Country Status (7)

Country Link
EP (1) EP0904107B1 (de)
JP (1) JP4046354B2 (de)
AT (1) ATE279947T1 (de)
AU (1) AU728657B2 (de)
CA (1) CA2249195A1 (de)
DE (1) DE69731289D1 (de)
WO (1) WO1997034631A1 (de)

Families Citing this family (730)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1105427A2 (de) * 1998-08-17 2001-06-13 Abgenix, Inc. Herstellung von modifizierten molekülen mit mit erhöhten halbwertszeiten
US6660843B1 (en) † 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1124961B9 (de) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietin substitute
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (de) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTID MIT EINER VARIANTE DER HUMANEN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU5717301A (en) 2000-04-21 2001-11-07 Amgen Inc Apo-ai/aii peptide derivatives
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2338512A1 (de) 2000-11-28 2011-06-29 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2008201419C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2387546T3 (es) 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
EP1684791A4 (de) 2003-10-27 2009-07-01 Amgen Inc Zusammensetzungen und verfahren zur modulierung einer immunantwort auf ein immunogenes therapeutisches mittel
ES2697327T3 (es) 2003-11-06 2019-01-23 Seattle Genetics Inc Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
EP1704166B1 (de) 2004-01-07 2015-04-29 Novartis Vaccines and Diagnostics, Inc. M-csf spezifischer monoclonaler antikörper und dessen verwendungen
EP1706428B1 (de) 2004-01-22 2009-09-23 MERCK PATENT GmbH Antikrebs-antikörper mit reduzierter komplementfixierung
AU2005207960A1 (en) 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1761540B1 (de) 2004-05-13 2016-09-28 Icos Corporation Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta
EP1771205B1 (de) 2004-06-18 2016-10-26 Ambrx, Inc. Neuartige antigen-bindende polypeptide und ihre verwendungen
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
CA2575838A1 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PT1699826E (pt) 2005-01-05 2009-06-17 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1868650B1 (de) 2005-04-15 2018-10-03 MacroGenics, Inc. Kovalente diabodies und ihre verwendung
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
PT2163562E (pt) 2005-06-21 2013-12-19 Xoma Us Llc Anticorpos de ligação a il 1 beta e respectivos fragmentos
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
EP4026840A1 (de) 2005-07-18 2022-07-13 Seagen Inc. Beta-glukuronid-linker-wirkstoffkonjugate
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
PT2573114T (pt) 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
CA2634083A1 (en) 2005-12-20 2007-06-28 Arana Therapeutics Limited Chimeric antibodies with part new world primate binding regions
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP1987064A4 (de) 2006-02-01 2010-04-07 Arana Therapeutics Ltd Domänen-antikörper-konstrukt
EP2010569A4 (de) 2006-03-20 2009-09-09 Xoma Technology Ltd Für gastrin spezifische humane antikörper, materialien und methoden
IN2014DN10515A (de) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP2027291A2 (de) 2006-04-27 2009-02-25 Pikamab, Inc. Verfahren und zusammensetzungen für antikörpertherapie
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2010123874A1 (en) 2009-04-20 2010-10-28 Oxford Biotherapeutics Ltd. Antibodies specific to cadherin-17
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2007147898A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008019199A2 (en) 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
ES2746925T3 (es) 2006-08-03 2020-03-09 Medimmune Ltd Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
EP2420252A1 (de) 2006-08-04 2012-02-22 Novartis AG EPHB3-spezifischer Antikörper und Verwendungen davon
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
WO2008022152A2 (en) 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19
JP5517619B2 (ja) 2006-08-18 2014-06-11 ノバルティス アーゲー Ｐｒｌｒ特異的抗体およびその使用
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
BRPI0715660B8 (pt) 2006-09-01 2021-05-25 Zymogenetics Inc anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
KR101519672B1 (ko) 2006-12-07 2015-05-29 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
CN108948177B (zh) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 融合分子与il-15变异体
AU2008255027B2 (en) 2007-05-14 2013-10-03 Astrazeneca Ab Methods of reducing eosinophil levels
EP2738257A1 (de) 2007-05-22 2014-06-04 Amgen Inc. Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
EP2176298B1 (de) 2007-05-30 2017-11-15 Xencor, Inc. Verfahren und zusammensetzungen zur hemmung von cd32b-expressionszellen
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
EP2158220B1 (de) 2007-06-26 2017-04-19 F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H Präsentieren von bindenden mitteln
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PT2489731E (pt) 2007-07-26 2014-09-15 Amgen Inc Enzimas aciltransferase de lecitina-colesterol modificadas
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
RU2015147300A (ru) 2007-08-29 2019-01-11 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JP5744522B2 (ja) 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１に特異的なヒト化抗体分子
CN103772502B (zh) 2007-12-07 2017-03-29 津莫吉尼蒂克斯公司 抗人il‑21单克隆抗体
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
AU2008343085B2 (en) 2007-12-20 2015-03-12 Xoma (Us) Llc Methods for the treatment of gout
EP2235058A2 (de) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid-antikörper und ihre verwendung
EP4098661A1 (de) 2007-12-26 2022-12-07 Xencor, Inc. Fc-varianten mit veränderter bindung an fcrn
CA2711736A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
EP3045475B1 (de) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-komplex-spezifische antikorper und verfahren zu ihrer verwendung
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102072896B1 (ko) * 2008-04-25 2020-02-03 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2815766B1 (de) 2008-08-05 2017-07-05 Novartis AG Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
EP2927244A1 (de) 2008-09-19 2015-10-07 MedImmune, LLC Gegen DLL4 gerichtete Antikörper und ihre Verwendung
KR102100066B1 (ko) * 2008-10-14 2020-04-10 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
EP2358392B1 (de) 2008-11-12 2019-01-09 MedImmune, LLC Antikörper-formulierung
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
EP2379595A2 (de) 2008-12-23 2011-10-26 AstraZeneca AB Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (de) 2009-04-20 2015-08-26 Gilead Calistoga LLC Verfahren zur behandlung von soliden tumoren
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
KR101860572B1 (ko) 2009-05-05 2018-05-24 암젠 인크 Ｆｇｆ２１ 돌연변이체 및 이의 용도
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
MX2011013457A (es) 2009-06-15 2012-05-08 Biokine Therapeutics Ltd Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
BRPI1014942A2 (pt) 2009-06-19 2019-09-24 Medimmune Llc "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
DK2486141T3 (en) 2009-10-07 2018-04-23 Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
MX2012005864A (es) 2009-11-20 2012-08-31 Amgen Inc Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
KR101790767B1 (ko) 2009-11-24 2017-10-26 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR101312829B1 (ko) 2009-12-30 2013-09-27 한화엘앤씨 주식회사 ＨＯ-1 유전자 및 ＴＮＦＲ1-Ｆｃ 유전자를 동시에 발현하는 형질전환 돼지 및 그의 제조 방법
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
GEP20166442B (en) 2010-03-04 2016-03-10 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP2927242A1 (de) 2010-04-09 2015-10-07 Amgen, Inc Btnl9-proteine, nukleinsäuren sowie antikörper und ihre verwendung
EP2558497A2 (de) 2010-04-15 2013-02-20 Amgen Inc. Menschlicher fgf-rezeptor und beta-klotho-bindeproteine
AU2011249783B9 (en) 2010-05-06 2014-11-06 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
AU2011258425B2 (en) 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
DK2606070T3 (en) 2010-08-20 2017-03-27 Novartis Ag Antibodies for the epidermal growth factor receptor 3 (HER3)
KR20140018837A (ko) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 노텀 단백질 조절 인자 및 사용 방법
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
SG188591A1 (en) 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
TWI585106B (zh) 2010-12-08 2017-06-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101276801B1 (ko) 2011-01-21 2013-06-19 한화엘앤씨 주식회사 ｓＴＮＦＲ1-Ｆｃ 유전자를 발현하는 형질전환 돼지 및 이의 용도
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
KR20140145947A (ko) 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
AU2012234335B2 (en) 2011-03-29 2016-09-01 Roche Glycart Ag Antibody Fc variants
ES2676499T3 (es) 2011-04-13 2018-07-20 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
CA2834589A1 (en) 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. Method for preparing fc-containing polypeptides having improved properties
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US8569462B2 (en) 2011-06-03 2013-10-29 Xoma Technology Ltd. Antibodies specific for TGF-beta and methods for treating thereof
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
SG10201604564XA (en) 2011-06-10 2016-07-28 Hanmi Science Co Ltd Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
JP6038905B2 (ja) 2011-06-17 2016-12-07 ハンミ サイエンス カンパニー リミテッド オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
WO2013003625A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Antibodies
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
RU2622077C2 (ru) 2011-09-05 2017-06-09 Ханми Сайенс Ко., Лтд. Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
ES2757473T3 (es) 2011-09-30 2020-04-29 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
TW201726745A (zh) 2011-09-30 2017-08-01 中外製藥股份有限公司 促進抗原消失的抗原結合分子
EP3939996A1 (de) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2899956T3 (es) 2011-11-04 2022-03-15 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
EP2776466B1 (de) 2011-11-11 2017-08-23 UCB Biopharma SPRL Albuminbindende antikörper und bindungsfragmenten davon
ES2852052T3 (es) 2011-11-17 2021-09-10 Pfizer Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
RU2739792C1 (ru) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
EA201491107A1 (ru) 2011-12-05 2014-11-28 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
BR112014015111A2 (pt) 2011-12-21 2017-06-13 Novartis Ag composições e processos para anticorpos que se direcionam ao fator p
EP2794653B1 (de) 2011-12-23 2019-03-13 Pfizer Inc Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2817338B1 (de) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3-modulatoren und verwendungsverfahren
JP6138108B2 (ja) 2012-02-24 2017-05-31 中外製薬株式会社 ＦｃγＲＩＩＢを介して抗原の消失を促進する抗原結合分子
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR102144069B1 (ko) 2012-05-15 2020-08-13 시애틀 지네틱스, 인크. 자가-안정화 링커 접합체
JP6294311B2 (ja) * 2012-05-23 2018-03-14 ジェネンテック， インコーポレイテッド 治療薬の選択方法
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
EP3892638A1 (de) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur beseitigung von aggregierten antigenen
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
EP3495387B1 (de) 2012-07-13 2021-09-01 Roche Glycart AG Bispezifische anti-vegf-/anti-ang-2-antikörper und deren verwendung bei der behandlung von vaskulären okulären erkrankungen
JP6448056B2 (ja) 2012-07-19 2019-01-09 アムジェン インコーポレイテッド ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
DK2889377T3 (da) 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
CN105121421B (zh) 2012-11-05 2020-10-02 辉瑞公司 司普力西欧他汀类似物
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
AR093387A1 (es) 2012-11-06 2015-06-03 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina
SG11201503469WA (en) 2012-11-07 2015-06-29 Pfizer Anti-notch3 antibodies and antibody-drug conjugates
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
SG11201503567SA (en) 2012-12-05 2015-06-29 Novartis Ag Compositions and methods for antibodies targeting epo
CN105051064A (zh) 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
EP2956468B1 (de) 2013-02-12 2020-06-10 Bristol-Myers Squibb Company Tangentialstromfiltration auf der basis von proteinrückfaltungsverfahren
ES2870802T3 (es) 2013-02-12 2021-10-27 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
AU2014218730B2 (en) 2013-02-22 2018-12-13 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
EP3616727B1 (de) 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulinanalogkonjugate und deren verwendung
NZ710564A (en) 2013-02-26 2020-06-26 Hanmi Pharm Ind Co Ltd Site-specific insulin conjugate
MX367817B (es) 2013-03-05 2019-09-06 Hanmi Pharm Ind Co Ltd Procedimiento de preparación mejorado para producción de alto rendimiento de conjugado polipeptídico fisiológicamente activo.
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112015021707A2 (pt) 2013-03-06 2017-12-05 Hadasit Med Res Service uso de células de planta que expresam um inibidor de polipeptídeo tnfalfa em terapia.
JP6454650B2 (ja) 2013-03-06 2019-01-23 プロタリクス リミテッド ＴＮＦαポリペプチド阻害剤を発現する植物細胞及び薬学的に許容される担体を含む医薬組成物
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
PT2968520T (pt) 2013-03-14 2021-08-19 Macrogenics Inc Moléculas biespecíficas que são imunorreativas com células efetoras imunitárias que expressam um recetor de ativação
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
CN105121470A (zh) 2013-03-15 2015-12-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
JP2016515524A (ja) 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
SG11201507619PA (en) 2013-03-15 2015-10-29 Ct For Drug Res And Dev Cytotoxic and anti-mitotic compounds, and methods of using the same
CN105143257B (zh) 2013-03-15 2020-10-27 艾伯维生物医疗股份有限公司 Fc变体
SG11201506766PA (en) 2013-03-15 2015-09-29 Dana Farber Cancer Inst Inc Therapeutic peptides
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
JP2016521744A (ja) 2013-06-13 2016-07-25 ファスト フォワード ファーマスーティカルズ ベー．フェー． 追加化合物が胆汁酸、胆汁酸誘導体、ｔｇｒ５受容体作動物質、ｆｘｒ作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのｃｄ４０シグナル伝達阻害物質および追加化合物
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
EP3027225B1 (de) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur modulierung der thermogenese mit transformierender wachstumsfaktor alpha
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
CA2922478C (en) 2013-08-26 2020-09-29 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
CA2922547C (en) 2013-08-28 2020-03-10 Stemcentrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CA2925416A1 (en) 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
EP3057605A1 (de) 2013-10-18 2016-08-24 Novartis AG Verfahren zur behandlung von diabetes und verwandten erkrankungen
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
EP3074424A4 (de) 2013-11-27 2017-06-14 Zymeworks Inc. Gegen her2 gerichtete bispezifische antigenbindende konstrukte
WO2015085210A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
PL3082878T3 (pl) 2013-12-19 2023-01-23 Seagen Inc. Łączniki karbaminianu metylenu do zastosowania z ukierunkowanymi koniugatami leku
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP3083630B1 (de) 2013-12-20 2019-08-21 Gilead Calistoga LLC Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
DK3087095T3 (da) 2013-12-24 2019-10-28 Argenx Bvba FcRn-antagonist og fremgangsmåder til anvendelse
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
CA2931986A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
CA2937168A1 (en) 2014-01-20 2015-07-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
BR112016017248A8 (pt) 2014-01-24 2018-04-17 Ngm Biopharmaceuticals Inc anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos
WO2015110935A1 (en) 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
KR20160120777A (ko) 2014-02-17 2016-10-18 시애틀 지네틱스, 인크. 친수성 항체-약물 컨쥬게이트
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3116903A2 (de) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Impfstoffzusammensetzungen und verfahren zur wiederherstellung der nkg2d-wegfunktion gegen krebs
HU231358B1 (hu) 2014-03-31 2023-03-28 Hanmi Pharm. Co., Ltd Eljárás fehérjék és peptidek oldhatóságának javítására immunoglobulin Fc fragmentum kapcsolás alkalmazása révén
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
EP3143138B1 (de) 2014-05-13 2022-03-23 BioAtla, Inc. Bedingt aktive biologische proteine
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
NZ764877A (en) 2014-06-04 2023-12-22 Biontech Res And Development Inc Human monoclonal antibodies to ganglioside gd2
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
ES2950789T3 (es) 2014-06-10 2023-10-13 Amgen Inc Polipéptidos de apelina
WO2015191726A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3157942B1 (de) 2014-06-23 2020-06-17 Novartis AG Ortsspezifische proteinmodifikationen
CN106659775B (zh) 2014-06-30 2021-08-06 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
SG10201912591RA (en) 2014-09-03 2020-02-27 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
JP2017532019A (ja) 2014-09-03 2017-11-02 バイオアトラ、エルエルシー 同じ真核細胞産生宿主における条件的活性型生物学的タンパク質の発見及び作製
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AR101875A1 (es) 2014-09-15 2017-01-18 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA038349B1 (ru) 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
EP3725808A1 (de) 2014-11-21 2020-10-21 Bristol-Myers Squibb Company Antikörper gegen cd73 und verwendungen davon
GB201421901D0 (en) 2014-12-09 2015-01-21 Cambridge Entpr Ltd A method of rational antibody design
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CR20170326A (es) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
BR112017013385A2 (pt) 2014-12-23 2018-02-06 Bristol-Myers Squibb Company anticorpos para tigit
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EP3241841A4 (de) 2014-12-30 2018-10-17 Hanmi Pharm. Co., Ltd. Glucagonderivat mit verbesserter stabilität
JP7152156B2 (ja) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 抗ｌａｐモノクローナル抗体による癌の処置
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
BR112017018706B1 (pt) 2015-03-20 2023-01-24 Pfizer Inc Agentes citotóxicos bifuncionais contendo o farmacoforo cti, composição farmacêutica e uso dos mesmos
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
JP6940479B2 (ja) 2015-08-03 2021-09-29 ノバルティス アーゲー Ｆｇｆ２１関連障害を処置する方法
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
SI3347377T1 (sl) 2015-09-09 2021-06-30 Novartis Ag Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3350216A1 (de) 2015-09-15 2018-07-25 Amgen Inc. Tetravalente bispezifische und tetraspezifische antigenbindende proteine und verwendungen davon
WO2017052329A1 (en) 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
AU2016332900C1 (en) 2015-09-29 2024-02-01 Amgen Inc. ASGR inhibitors
MX2018003689A (es) 2015-09-29 2018-04-30 Celgene Corp Proteinas de union a pd-1 y metodos para usarlas.
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
EP3370771A4 (de) 2015-11-03 2019-06-19 Ambrx, Inc. Anti-cd3-folat-konjugate und deren verwendungen
JP6412906B2 (ja) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 化合物、リンカー−薬物およびリガンド−薬物複合体
US11213586B2 (en) 2015-11-19 2022-01-04 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
JP2019500327A (ja) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
JP2019501131A (ja) 2015-12-04 2019-01-17 シアトル ジェネティックス， インコーポレイテッド 四級化チューブリシン化合物の複合体
KR20210016479A (ko) 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20180089510A (ko) 2015-12-18 2018-08-08 노파르티스 아게 CD32b를 표적화하는 항체 및 그의 사용 방법
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
IL260318B2 (en) 2015-12-31 2024-02-01 Hanmi Pharm Ind Co Ltd A triple agonist for glucagon/GLP–1/GIP receptors
EP3402819A1 (de) 2016-01-11 2018-11-21 Novartis AG Immunstimulierende humanisierte monoklonale antikörper gegen menschliches interleukin-2 und fusionsproteine davon
EP3405492B1 (de) 2016-01-21 2020-10-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
EP3423489A1 (de) 2016-03-04 2019-01-09 The Rockefeller University Antikörper gegen cd40 mit erhöhter agonistischer aktivität
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
AR107823A1 (es) 2016-03-07 2018-06-06 Hanmi Pharm Ind Co Ltd Derivados de polietilenglicol y uso de los mismos
CA3017622A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
AU2017271593B2 (en) * 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
CN109414492A (zh) 2016-06-16 2019-03-01 小利兰斯坦福大学理事会 针对cd81的人源化和嵌合单克隆抗体
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
CN109641035A (zh) 2016-06-29 2019-04-16 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
EP3481864A1 (de) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2018052556A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
CA3032559C (en) 2016-08-03 2022-04-19 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
BR112019001945A2 (pt) 2016-08-09 2019-05-07 Seattle Genetics, Inc. composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
AU2017327723B2 (en) 2016-09-14 2022-11-17 Teneobio, Inc. CD3 binding antibodies
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
JP2019531284A (ja) 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
CA3037844A1 (en) 2016-09-23 2018-03-29 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR20230144096A (ko) 2016-10-18 2023-10-13 씨젠 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
JP7096240B2 (ja) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合ｃ５の定量化方法
CA3200275A1 (en) 2016-10-21 2018-04-26 Nantcell, Inc. Multimeric il-15-based molecules
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
KR20190080949A (ko) 2016-11-23 2019-07-08 바이오버라티브 테라퓨틱스 인크. 응고 인자 ｉｘ 및 응고 인자 ｘ에 결합하는 이중특이적 항체
CN110291103A (zh) 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
BR112019011651A2 (pt) 2016-12-07 2020-01-07 Agenus Inc. Anticorpos anti-cttla-4 e métodos de uso dos mesmos
CN110300599A (zh) 2016-12-07 2019-10-01 艾吉纳斯公司 抗体和其使用方法
EP3556399A1 (de) 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Auf das gehirn abzielendes langwirkendes proteinkonjugat
KR20190099256A (ko) 2016-12-23 2019-08-26 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
IL267538B1 (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CA3049424A1 (en) 2017-01-06 2018-07-12 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
EP3573995A1 (de) 2017-01-24 2019-12-04 Pfizer Inc. Calicheamicin-derivate und antikörper-wirkstoff-konjugate davon
JP2020506932A (ja) 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
US11925691B2 (en) 2017-02-07 2024-03-12 Hanmi Pharm. Co., Ltd. Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
MX2019009498A (es) 2017-02-08 2019-10-02 Novartis Ag Anticuerpos mimeticos de fgf21 y usos de los mismos.
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
CN110785435B (zh) 2017-03-06 2024-01-23 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CN110709417B (zh) 2017-04-07 2023-10-31 美天施生物科技有限责任两合公司 具有突变人IgG4的多肽
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
EP3612560A1 (de) * 2017-04-21 2020-02-26 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
EP3615564A1 (de) 2017-04-24 2020-03-04 Alexion Pharmaceuticals, Inc. Inhibitorfusionsproteine von antikörperimmunzellen
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
EP3625251A1 (de) 2017-05-15 2020-03-25 University Of Rochester Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
US20200270334A1 (en) 2017-05-24 2020-08-27 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
SG11202000115SA (en) 2017-07-07 2020-02-27 Hanmi Pharmaceutical Co Ltd Novel therapeutic enzyme fusion protein and use thereof
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3658184B1 (de) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. Hochkonzentrierte anti-c5-antikörperformulierungen
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019046313A1 (en) 2017-08-28 2019-03-07 Altor Bioscience Llc IL-15 BASED FUSIONS WITH IL-7 AND IL-21
SG11202002093TA (en) 2017-09-13 2020-04-29 Teneobio Inc Heavy chain antibodies binding to ectoenzymes
MX2020004453A (es) 2017-09-28 2020-07-24 Hanmi Pharm Ind Co Ltd Conjugados de accion prolongada de derivados de glp-2.
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
CN111406073A (zh) 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
WO2019066609A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
KR20200060496A (ko) 2017-10-04 2020-05-29 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 그의 용도
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
BR112020008514A2 (pt) 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
WO2019113393A1 (en) 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CR20200322A (es) 2017-12-22 2021-01-12 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22
NZ765453A (en) 2017-12-22 2024-03-22 Hanmi Pharm Co Ltd Therapeutic enzyme fusion protein having novel structure and use thereof
MX2020006715A (es) 2017-12-27 2020-08-20 Teneobio Inc Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
CN111788227A (zh) 2017-12-27 2020-10-16 百时美施贵宝公司 抗cd40抗体及其用途
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
US20220089720A1 (en) 2018-01-12 2022-03-24 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
AU2019207915A1 (en) 2018-01-12 2020-07-16 Amgen Inc. PAC1 antibodies and uses thereof
CA3090805A1 (en) 2018-02-20 2019-08-29 Seattle Genetics, Inc. Hydrophobic auristatin f compounds and conjugates thereof
BR112020017296A2 (pt) * 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019190293A1 (ko) 2018-03-30 2019-10-03 한미약품 주식회사 뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
EP3792276A4 (de) 2018-04-26 2022-02-16 Good T Cells, Inc. Neuartiges fusionsprotein und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs damit
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
CA3099450A1 (en) 2018-05-08 2019-11-14 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN112384531A (zh) 2018-06-01 2021-02-19 诺华股份有限公司 针对bcma的结合分子及其用途
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
PL3806884T3 (pl) 2018-06-15 2023-11-20 Amyl Therapeutics Ogólny motyw oddziaływania z amyloidem (gaim)
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
KR20210032311A (ko) 2018-07-20 2021-03-24 테네오바이오, 인코포레이티드 Cd19에 결합하는 중쇄 항체
US20210347849A1 (en) 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases
MX2021003169A (es) 2018-09-21 2021-08-11 Teneobio Inc Metodos para purificar anticuerpos multiespecificos, heterodimericos.
CN110964116A (zh) 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US20210338779A1 (en) 2018-10-04 2021-11-04 Hanmi Pharm. Co., Ltd Therapeutic use of glucagon and combination including the same
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
US20210393745A1 (en) 2018-10-10 2021-12-23 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
AU2019367218A1 (en) 2018-10-26 2021-06-03 TeneoFour, Inc. Heavy chain antibodies binding to CD38
EP3880708A1 (de) 2018-11-16 2021-09-22 Bristol-Myers Squibb Company Anti-nkg2a-antikörper und verwendungen davon
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
MX2021007368A (es) 2018-12-21 2021-07-15 Avidity Biosciences Inc Anticuerpos anti-receptor de transferrina y usos de los mismos.
KR20200078413A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
KR20200078414A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
CA3127236A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
EP3947470A1 (de) 2019-04-05 2022-02-09 TeneoBio, Inc. An psma bindende schwerkettige antikörper
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
KR20220006519A (ko) 2019-05-10 2022-01-17 다케다 야쿠힌 고교 가부시키가이샤 항체 약물 접합체
TW202100559A (zh) 2019-05-21 2021-01-01 瑞士商諾華公司 Cd19 結合分子及其用途
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
CA3141690A1 (en) 2019-05-30 2020-12-03 Amgen Inc. Engineering the hinge region to drive antibody dimerization
CA3142283A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
MA56102A (fr) 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
NZ777755A (en) 2019-06-28 2023-05-26 Hanmi Pharm Ind Co Ltd Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
CN114174536A (zh) 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
CN114144435A (zh) 2019-07-15 2022-03-04 百时美施贵宝公司 针对人trem-1的抗体及其用途
MX2022000758A (es) 2019-07-18 2022-02-11 Hanmi Pharm Ind Co Ltd Procedimiento novedoso para preparar un conjugado de farmaco de accion prolongada mediante la preparacion de un intermedio.
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
BR112022003740A2 (pt) 2019-08-30 2022-05-31 Agenus Inc Anticorpos anti-cd96 e métodos de uso dos mesmos
EP4025253B1 (de) 2019-09-05 2024-03-20 Pharma Mar, S.A. Arzneimittel-antikörper-konjugate
EP4031578A1 (de) 2019-09-18 2022-07-27 Novartis AG Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
BR112022004863A2 (pt) 2019-09-19 2022-06-07 Seagen Inc Composição conjugado de ligante fármaco, compostos conjugado de ligante-fármaco e conector de fármaco, e, formulação farmaceuticamente aceitável
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
JP2022551282A (ja) 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
AU2020371784A1 (en) 2019-10-24 2022-06-02 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
BR112022012191A2 (pt) 2019-12-20 2022-12-13 Amgen Inc Construtos de anticorpos multiespecíficos agonistas de cd40 visados à mesotelina para o tratamento de tumores sólidos
KR20210082120A (ko) 2019-12-24 2021-07-02 한미약품 주식회사 Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
BR112022013741A2 (pt) 2020-01-13 2022-10-11 Hanmi Pharm Ind Co Ltd Composição farmacêutica
EP4110402A1 (de) 2020-02-25 2023-01-04 Mediboston, Inc. Camptothecinderivate und konjugate davon
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
US20230126881A1 (en) * 2020-03-27 2023-04-27 Alnylam Pharmaceuticals, Inc. Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20220161378A (ko) 2020-03-27 2022-12-06 어비디티 바이오사이언시스 인크. 근이영양증의 치료용 조성물 및 방법
KR20210121585A (ko) 2020-03-30 2021-10-08 한국세라믹기술원 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
JP2023519930A (ja) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体
IL296669A (en) 2020-04-03 2022-11-01 Hanmi Pharm Ind Co Ltd A medicinal preparation for the prevention or treatment of mucositis caused by radiotherapy, chemotherapy or their combination, which includes glp-2 derivatives or their long-term conjugates
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
US20230158117A1 (en) 2020-04-20 2023-05-25 Hanmi Pharm. Co., Ltd. Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof and method using the same
AR121881A1 (es) 2020-04-20 2022-07-20 Genzyme Corp Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
AU2021260792A1 (en) 2020-04-21 2022-11-24 Pharma Mar, S.A. Drug antibody conjugates
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
EP4186564A1 (de) 2020-04-29 2023-05-31 Teneoone, Inc. Multispezifische schwerkettige antikörper mit modifizierten schwerkettigen konstanten regionen
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
BR112022023738A2 (pt) 2020-05-22 2023-01-31 Hanmi Pharm Ind Co Ltd Formulação líquida
EP4154868A1 (de) 2020-05-22 2023-03-29 Hanmi Pharm. Co., Ltd. Flüssige formulierung eines langwirkenden konjugats eines glucagonderivats
KR20210144609A (ko) 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
JP2023526550A (ja) 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド Ｇｌｐ－２の持続型結合体の液状製剤
IL299149A (en) 2020-06-26 2023-02-01 Amgen Inc IL-10 mutants and their related proteins
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
IL299778A (en) 2020-07-15 2023-03-01 Hanmi Pharm Ind Co Ltd Therapeutic use of a glucagon derivative or its combination to treat liver disease
US20220016212A1 (en) 2020-07-17 2022-01-20 Spectrum Pharmaceuticals, Inc. Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
MX2023000699A (es) 2020-07-17 2023-04-18 Hanmi Pharmaceutical Co Ltd Uso terapéutico de combinación que comprende un conjugado de acción prolongada triple agonista o agonista triple.
EP4230216A1 (de) 2020-07-24 2023-08-23 Jiangsu Gensciences Inc. Insulin-fc-fusionsprotein und anwendung davon
AU2021320870A1 (en) 2020-08-06 2023-04-06 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
IL300257A (en) 2020-08-10 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 antibodies for the treatment and prevention of COVID-19
MX2023001601A (es) 2020-08-14 2023-03-07 Hanmi Pharmaceutical Co Ltd Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
AU2021324792A1 (en) 2020-08-14 2023-02-23 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
MX2023002125A (es) 2020-08-20 2023-04-26 Amgen Inc Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
US20230355789A1 (en) 2020-09-25 2023-11-09 Hanmi Pharm. Co., Ltd. Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
CN116437967A (zh) 2020-09-25 2023-07-14 韩美药品株式会社 包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物
JP2023543043A (ja) 2020-09-25 2023-10-12 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の多発性硬化症の治療用途
EP4225786A2 (de) 2020-10-07 2023-08-16 Amgen Inc. Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
WO2022082005A1 (en) 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
US20230382970A1 (en) 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same
CN116390769A (zh) 2020-10-16 2023-07-04 韩美药品株式会社 包括胰高血糖素/glp-1/gip三重激动剂或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物
JP2023546429A (ja) 2020-10-16 2023-11-02 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｇｉｐ誘導体、その持続型結合体、及びそれを含む薬学的組成物
WO2022080987A1 (ko) 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
US20230390362A1 (en) 2020-10-16 2023-12-07 Hanmi Pharm. Co., Ltd. Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatment of sequelae following respiratory infectious diseases
US20230381279A1 (en) 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating lupus-related diseases comprising gip derivative or long-acting conjugate thereof
EP4240758A1 (de) 2020-11-04 2023-09-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
PE20231947A1 (es) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
EP4244246A1 (de) 2020-11-10 2023-09-20 Amgen Inc. Neue linker von multispezifischen antigenbindenden domänen
KR20220065720A (ko) 2020-11-13 2022-05-20 한미약품 주식회사 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도
AU2021378707A1 (en) 2020-11-13 2023-06-01 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
KR20220086522A (ko) 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도
TW202247856A (zh) 2020-12-24 2022-12-16 南韓商韓美藥品股份有限公司 新穎之三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑及其用途
CN116940370A (zh) 2020-12-24 2023-10-24 韩美药品株式会社 用于预防或治疗短肠综合征的促胰岛素肽和glp-2的组合疗法
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
JP2024505636A (ja) 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗ｓａｒｓ－ｃｏｖ－２中和抗体
JP2024505943A (ja) 2021-01-29 2024-02-08 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｇｉｐ誘導体、またはその持続型結合体を含む肺疾患の予防用または治療用の薬学的組成物
EP4298130A2 (de) 2021-02-25 2024-01-03 Teneobio, Inc. Anti-psma-antikörper und car-t-strukturen
CN116917327A (zh) 2021-02-26 2023-10-20 特尼奥生物股份有限公司 抗muc1-c抗体及car-t结构
EP4308171A1 (de) 2021-03-18 2024-01-24 Seagen Inc. Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen
EP4308170A1 (de) 2021-03-18 2024-01-24 Seagen Inc. Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen
KR20220136285A (ko) 2021-03-31 2022-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4320158A1 (de) 2021-04-06 2024-02-14 Teneobio, Inc. Anti-cd19-antikörper und car-t-strukturen
CA3209923A1 (en) 2021-04-09 2022-10-13 Seon Myeong Lee Pharmaceutical composition for preventing or treating chronic kidney disease containing glucagon derivative
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
CN117651714A (zh) 2021-04-20 2024-03-05 美国安进公司 多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
AU2022264339A1 (en) 2021-04-28 2023-11-09 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
CA3224001A1 (en) 2021-06-25 2022-12-29 Amgen Inc. Treatment of cardiovascular disease with trem-1 antigen binding proteins
KR20230004135A (ko) 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
WO2023031615A1 (en) 2021-09-02 2023-03-09 Djs Antibodies Ltd Polypeptides
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023056362A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
US20230192843A1 (en) 2021-10-14 2023-06-22 Teneobio, Inc. Mesothelin binding proteins and uses thereof
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023091968A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023242361A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn binding molecules and methods of use
WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
WO2024003376A1 (en) 2022-07-01 2024-01-04 Alk-Abelló A/S Displacers of ige-fceri
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024023735A1 (en) 2022-07-27 2024-02-01 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
WO2024036139A2 (en) 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. Antibodies binding to clec12a
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
CA2118508A1 (en) * 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004689A1 (en) * 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life

Also Published As

Publication number Publication date
JP4046354B2 (ja) 2008-02-13
AU728657B2 (en) 2001-01-18
EP0904107B1 (de) 2004-10-20
EP0904107A1 (de) 1999-03-31
CA2249195A1 (en) 1997-09-25
DE69731289D1 (de) 2004-11-25
AU1985097A (en) 1997-10-10
JP2000507816A (ja) 2000-06-27
WO1997034631A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
ATE279947T1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1993022332A3 (en) Recombinant production of immunoglobulin-like domains in prokaryotic cells
PL415463A1 (pl) Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE522610T1 (de) Menschliche, metabotrope glutamatrezeptor- subtypen (hmr6) und verwandte dns-verbindungen
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
KR950702635A (ko) 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
PT96097A (pt) Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
DK1386931T3 (da) Human neurotriminhomolog
WO2001064913A3 (en) Cell cycle proteins associated with rad9, compositions and methods of use
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
ATE290549T1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein,sowie zusammensetzungen, verfahren und verwendungen
DE59914878D1 (de) Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
SE9804491D0 (sv) Novel fibronectin-binding protein
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
PT1241185E (pt) Acido nucleico que e amplificado em tumores humanos e materiais e metodos relacionados
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
DE69927190D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE405590T1 (de) Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
ATE404585T1 (de) Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
ATE402954T1 (de) Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
ATE492640T1 (de) Loslösendes protein 5 - ucp5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties